| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 10. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | digoxin immune fab (DigiFab®) |
| Formulation | 40 mg/vial powder for solution for infusion |
| Reference number | 672 |
| Indication | Treatment of known or strongly suspected, life-threatening or potentially life-threatening digoxin or digitoxin toxicity, where measures beyond the withdrawal of the digitialis glycoside and correction of any serum electrolyte abnormality are felt to be necessary |
| Company | Beacon Pharmaceuticals Ltd |
| BNF chapter | Immunological products & vaccines |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 01/03/2012 |